vs
Caesarstone Ltd.（CSTE）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Caesarstone Ltd.的季度营收约是RIGEL PHARMACEUTICALS INC的1.4倍（$94.4M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -93.1%，领先477.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -57.8%）
凯撒斯通有限公司成立于1987年，总部位于以色列，是一家上市建材企业，主要生产销售石英、陶瓷、矿物及融合工艺饰面材料，产品广泛应用于厨房台面、化妆台面板、墙面装饰、室内地板及各类整体室内设计项目，目前在美国纳斯达克上市。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CSTE vs RIGL — 直观对比
营收规模更大
CSTE
是对方的1.4倍
$69.8M
净利率更高
RIGL
高出477.2%
-93.1%
两年增速更快
RIGL
近两年复合增速
-57.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.4M | $69.8M |
| 净利润 | $-87.9M | $268.1M |
| 毛利率 | 15.5% | 91.5% |
| 营业利润率 | -87.2% | 33.2% |
| 净利率 | -93.1% | 384.0% |
| 营收同比 | — | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $-2.55 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSTERIGL
| Q4 25 | $94.4M | $69.8M | ||
| Q3 25 | $345.4M | $69.5M | ||
| Q2 25 | $237.7M | $101.7M | ||
| Q1 25 | — | $53.3M | ||
| Q4 24 | — | $57.6M | ||
| Q3 24 | $436.7M | $55.3M | ||
| Q2 24 | $294.3M | $36.8M | ||
| Q1 24 | $150.6M | $29.5M |
净利润CSTERIGL
| Q4 25 | $-87.9M | $268.1M | ||
| Q3 25 | $-18.5M | $27.9M | ||
| Q2 25 | $-14.3M | $59.6M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $-57.4M | $12.4M | ||
| Q2 24 | $-56.6M | $-1.0M | ||
| Q1 24 | $-3.9M | $-8.2M |
毛利率CSTERIGL
| Q4 25 | 15.5% | 91.5% | ||
| Q3 25 | 22.5% | 93.2% | ||
| Q2 25 | 23.7% | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | 15.7% | 85.5% | ||
| Q2 24 | 14.1% | 92.4% | ||
| Q1 24 | 19.7% | 93.1% |
营业利润率CSTERIGL
| Q4 25 | -87.2% | 33.2% | ||
| Q3 25 | -5.5% | 40.9% | ||
| Q2 25 | -6.2% | 60.1% | ||
| Q1 25 | — | 23.9% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | -12.6% | 25.4% | ||
| Q2 24 | -18.0% | 1.2% | ||
| Q1 24 | -3.9% | -23.6% |
净利率CSTERIGL
| Q4 25 | -93.1% | 384.0% | ||
| Q3 25 | -5.4% | 40.2% | ||
| Q2 25 | -6.0% | 58.6% | ||
| Q1 25 | — | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | -13.1% | 22.5% | ||
| Q2 24 | -19.2% | -2.8% | ||
| Q1 24 | -2.6% | -27.9% |
每股收益（稀释后）CSTERIGL
| Q4 25 | $-2.55 | $14.11 | ||
| Q3 25 | $-0.54 | $1.46 | ||
| Q2 25 | $-0.41 | $3.28 | ||
| Q1 25 | — | $0.63 | ||
| Q4 24 | — | $0.82 | ||
| Q3 24 | $-1.67 | $0.70 | ||
| Q2 24 | $-1.64 | $-0.06 | ||
| Q1 24 | $-0.11 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $58.4M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $139.2M | $391.5M |
| 总资产 | $398.4M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CSTERIGL
| Q4 25 | $58.4M | $155.0M | ||
| Q3 25 | — | $137.1M | ||
| Q2 25 | — | $108.4M | ||
| Q1 25 | — | $77.1M | ||
| Q4 24 | — | $77.3M | ||
| Q3 24 | — | $61.1M | ||
| Q2 24 | — | $49.1M | ||
| Q1 24 | — | $49.5M |
总债务CSTERIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | $-12.6M | $60.0M |
股东权益CSTERIGL
| Q4 25 | $139.2M | $391.5M | ||
| Q3 25 | $271.6M | $117.6M | ||
| Q2 25 | $271.6M | $81.9M | ||
| Q1 25 | — | $18.6M | ||
| Q4 24 | — | $3.3M | ||
| Q3 24 | $315.1M | $-14.6M | ||
| Q2 24 | $315.1M | $-29.9M | ||
| Q1 24 | $315.1M | $-31.7M |
总资产CSTERIGL
| Q4 25 | $398.4M | $513.6M | ||
| Q3 25 | $549.0M | $242.5M | ||
| Q2 25 | $549.0M | $206.7M | ||
| Q1 25 | — | $176.0M | ||
| Q4 24 | — | $164.0M | ||
| Q3 24 | $579.9M | $139.4M | ||
| Q2 24 | $579.9M | $128.4M | ||
| Q1 24 | $579.9M | $126.5M |
负债/权益比CSTERIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-38.0M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $-47.1M | — |
| 自由现金流率自由现金流/营收 | -49.8% | — |
| 资本支出强度资本支出/营收 | 9.6% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $38.6M | — |
8季度趋势，按日历期对齐
经营现金流CSTERIGL
| Q4 25 | $-38.0M | $22.0M | ||
| Q3 25 | $35.0M | $24.0M | ||
| Q2 25 | $18.7M | $30.5M | ||
| Q1 25 | — | $-893.0K | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | $53.3M | $21.7M | ||
| Q2 24 | $25.1M | $302.0K | ||
| Q1 24 | $7.9M | $-5.0M |
自由现金流CSTERIGL
| Q4 25 | $-47.1M | — | ||
| Q3 25 | $26.7M | — | ||
| Q2 25 | $14.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $44.6M | — | ||
| Q2 24 | $20.7M | — | ||
| Q1 24 | $5.0M | — |
自由现金流率CSTERIGL
| Q4 25 | -49.8% | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | 6.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 7.0% | — | ||
| Q1 24 | 3.3% | — |
资本支出强度CSTERIGL
| Q4 25 | 9.6% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.9% | — |
现金转化率CSTERIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSTE
| America's | $53.0M | 56% |
| USA | $41.4M | 44% |
RIGL
暂无分部数据
